Chevy Chase Trust Holdings LLC Has $12.71 Million Position in STERIS plc $STE

Chevy Chase Trust Holdings LLC raised its stake in STERIS plc (NYSE:STE) by 0.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 52,896 shares of the medical equipment provider’s stock after acquiring an additional 369 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.05% of STERIS worth $12,707,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Geneos Wealth Management Inc. increased its position in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in STERIS in the first quarter valued at about $37,000. Golden State Wealth Management LLC raised its holdings in STERIS by 503.0% during the 1st quarter. Golden State Wealth Management LLC now owns 199 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 166 shares during the period. Costello Asset Management INC bought a new position in STERIS during the 1st quarter worth about $45,000. Finally, Wayfinding Financial LLC acquired a new position in STERIS during the 1st quarter worth approximately $46,000. Institutional investors own 94.69% of the company’s stock.

Analyst Ratings Changes

STE has been the topic of several recent analyst reports. Morgan Stanley boosted their price target on STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Finally, KeyCorp increased their price objective on shares of STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a research note on Tuesday, July 22nd. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, STERIS has an average rating of “Moderate Buy” and a consensus price target of $273.50.

STERIS Stock Down 0.0%

Shares of NYSE STE opened at $240.25 on Monday. The company’s fifty day simple moving average is $245.08 and its 200 day simple moving average is $236.43. The firm has a market cap of $23.66 billion, a PE ratio of 36.79 and a beta of 1.01. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. STERIS plc has a 12-month low of $200.98 and a 12-month high of $253.00.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $2.34 EPS for the quarter, beating the consensus estimate of $2.32 by $0.02. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The firm had revenue of $1.40 billion during the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the company posted $2.03 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. As a group, sell-side analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 26th. Shareholders of record on Thursday, September 4th were paid a dividend of $0.63 per share. This is a boost from STERIS’s previous quarterly dividend of $0.57. The ex-dividend date was Thursday, September 4th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s dividend payout ratio (DPR) is 38.59%.

Insider Transactions at STERIS

In other STERIS news, Director Mohsen Sohi sold 4,110 shares of STERIS stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $241.96, for a total transaction of $994,455.60. Following the transaction, the director owned 22,361 shares of the company’s stock, valued at $5,410,467.56. This trade represents a 15.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Renato Tamaro sold 3,204 shares of the company’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $249.24, for a total value of $798,564.96. Following the completion of the transaction, the vice president owned 7,221 shares of the company’s stock, valued at $1,799,762.04. This trade represents a 30.73% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,868 shares of company stock worth $4,585,389. Company insiders own 1.07% of the company’s stock.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.